echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood Cancer J: Is R-CEOP the first choice for patients with anthracycline DLBCL who are not suitable for first-line treatment?

    Blood Cancer J: Is R-CEOP the first choice for patients with anthracycline DLBCL who are not suitable for first-line treatment?

    • Last Update: 2022-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    R-CHOP is the standard protocol for diffuse large B-cell lymphoma (DLBCL), but as with all anthracyclines, doxorubicin has dose-dependent cardiotoxicity, particularly in patients with congestive heart failure and in patients with previous exposure to


    However, it is unethical to perform RCTs in patients who are not candidates for anthracycline therapy, as patients randomly assigned to the doxorubicin group experience severe cardiotoxicity due to their cardiac insufficiency and therefore tendance score matching


    Research design

    References

    Diana Al-Sarayfi,et al.


    : ,


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.